Key result
Perioperative levosimendan reduced postoperative mortality overall, but trials published after 2015 showed no mortality benefit.
Why the study?
Does perioperative administration of levosimendan reduce postoperative mortality and length of stay in adult patients undergoing cardiac surgery?
Meta-Analysis (n=3,239)
Does perioperative administration of levosimendan reduce postoperative mortality and length of stay in adult patients undergoing cardiac surgery?
While overall historical data suggested a mortality benefit, evidence from recent trials (post-2015) indicates that perioperative levosimendan does not improve clinical outcomes in adult patients undergoing cardiac surgery.
Answers are grounded in this paper and cite their sources.
Recent trials show no mortality benefit with perioperative levosimendan; challenges earlier pooled evidence and does not support routine use.
It is currently unknown whether levosimendan can improve clinical outcomes in patients undergoing cardiac surgery. This meta-analysis aimed to assess the effect of levosimendan on mortality and the duration of intensive care unit (ICU) and hospital stay in adult patients undergoing cardiac surgery. A comprehensive search for eligible articles was conducted in PubMed, OVID and Cochrane databases of clinical trials and the Web of Science from database inception to August 2017. Stata/SE 11.0 was used to calculate the pooled odds ratio for postoperative mortality and the pooled standardized mean difference (SMD) for the duration of ICU stay and hospital stay. A total of 30 randomized controlled trials were included in the final analysis; the pooled results indicated that perioperative administration of levosimendan was associated with a reduction in postoperative mortality [5.8% vs 8.5%; odds ratio 0.66, 95% confidence interval 0.50-0.86, P = 0.002; I2 = 17.1%; 25 trials; 3239 patients] and length of ICU stay (SMD -0.32, 95% CI -0.58 to 0.06, P = 0.017; I2 = 88.0%; 23 trials; 2536 patients) compared with the control group but not in length of hospital stay (SMD -0.41, 95% CI -0.89 to 0.07, P = 0.094; I2 = 95.9%; 18 trials; 2047 patients). A subanalysis was conducted for trials published after 2015, and it suggested that levosimendan could not reduce the postoperative mortality (odds ratio = 0.91, 95% CI 0.63-1.31, P = 0.626; I2 = 0.9%), length of ICU stay (SMD -0.03, 95% CI -0.32 to 0.27, P = 0.850; I2 = 81.2%) or length of hospital stay (SMD 0.06, 95%CI -0.43 to 0.54, P = 0.821; I2 = 91.3%). To summarize, the evidence from studies published in the last 3 years indicated that perioperative administration of levosimendan was not associated with better clinical outcomes in adult patients undergoing cardiac surgery.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2018) conducted a meta-analysis in cardiac surgery (n=3,239). Levosimendan vs. Control group was evaluated on postoperative mortality (OR 0.66, 95% CI 0.50-0.86, p=0.002). Perioperative levosimendan reduced postoperative mortality overall, but trials published after 2015 showed no mortality benefit.
Synapse has enriched 10 related papers. Consider them for comparative context: